Healthify targets US market for growth and major source of revenue

“From a business traction perspective, we do about $2 million a year in recurring revenue, which is still small,” said Tushar Vashisht, co-founder and CEO of Healthify. Mint. “We’ll hit double-digit millions next year and I think it will be the primary revenue generator for our US business by 2027.”

As millions of people seek to improve their health, nutrition and diet monitoring have become an increasing focus for health-conscious consumers around the world. According to Grand View Research, the global diet and nutrition apps market size was valued at $2.14 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 13.4% from 2024 to 2030, reaching $4.56 billion by 2030.

Strategy in the USA

With increased focus on the US, the company shifted its entire focus to this market, including reallocation of resources. “We are pouring much of the engineering product and technology experience into our global plans. Most of our research costs go to the US,” Vashisht said.

To strengthen its presence in the U.S., Healthify is looking to partner with insurance providers in the country as well as companies that offer reimbursement as a service to registered dietitians. Most healthcare services here, including diet monitoring and nutrition, are dependent on insurance.

Through a partnership such as a reimbursement service, Healthify is able to offer its users the services of registered dietitians, paid for by insurance providers. “These partnerships are what will enable us to grow and expand into the market in the US,” Vashisht said.

It’s also partnering with dietitian providers to help strengthen its business and is in the process of talking to several companies, including dietitian startup Berry Street, which raised $50 million in a Series B round from Goldman Sachs in February of this year at a $500 million valuation.

“With preventive health taking center stage globally, weight management and adequate nutrition become critically important, making dietitian collaborations both beneficial for improving outcomes and a viable approach to increasing revenue within the US healthcare system,” said Nilaya Varma, co-founder and group CEO of consulting firm Primus Partners.

Like many consumer-facing apps around the world, Healthify operates on a ‘freemium’ model; It offers some features for free while locking others behind a paywall, thus encouraging users to pay in-app. So the company says it has tens of thousands of users since entering the US market, and “thousands” of them are paying customers.

The company will also eventually bring its bonus Weight loss program HealthifyRx to USA. Healthify’s complete software platform goes live this month. It was previously temporarily released in the US with the calorie counting tool Snap. It launched its AI-powered coaching program in March and its AI-powered continuous glucose monitoring offering in August.

homecoming work

While insurance providers are Healthify’s focus in the US, the company is looking to establish partnerships with pharmaceutical companies and then healthcare providers. Insurance companies are at the bottom of the list.

Healthify announced a partnership with Novo Nordisk for a patient assistance program in India. The company, which originally started as a calorie tracking app, is investing heavily in offering surrogate assistance to patients using GLP-1 medications for weight loss.

GLP-1 (glucagon-like peptide-1) agonists are a class of medications that mimic the GLP-1 hormone in the body that controls appetite and blood sugar. According to Goldman Sachs, the worldwide pharmaceutical market is expected to reach $95 billion by 2030.

The emerging anti-obesity drug market in India is experiencing rapid expansion. It grew from: ₹133 crore in March 2021 ₹576 crore in March 2025, according to data from pharma intelligence platform Pharmarack. The market is dominated by Eli Lilly’s tirzepatide, which was launched under the brand name Mounjaro in late March, and Novo Nordisk’s semaglutide, sold under the brand name Wegovy. These drugs quickly took over the market. Mounjaro became the best-selling pharmaceutical brand in India in October. ₹100 crore in monthly sales.

Volumes are expected to increase significantly next year as semaglutide loses patent exclusivity in March 2026 and prices decline. including many Indian pharmaceutical manufacturers Dr Reddy’s, Sun Pharma, Mankind Pharma and Natco Pharma are planning to launch cheaper generic drugs once the patents expire.

But maintaining profitability remains the ultimate goal of Healthify’s business in India. In fact, Vashisht said, “We expect to be profitable for most of the months this year,” and he is confident that next year will be “cash flow positive.”

The company is aiming for a public listing in the next 2-3 years as Healthify looks to grow its revenue in the US. But to achieve this, the company aims to generate hundreds of millions in revenue and achieve high profitability.

“For companies operating in both the US and India, it is important that the model works in a high-cost market like the US while also being valid in a price-sensitive market like India,” said Primus Partners’ Varma. “In this environment, real user outcomes and sustainable engagement become key drivers of long-term financial reliability.”